Exhibit 99.1 Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., May 14, 2024 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology compan ...